# Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

> **NCT03126110** · PHASE1,PHASE2 · COMPLETED · sponsor: **Incyte Biosciences International Sàrl** · enrollment: 145 (actual)

## Conditions studied

- Advanced Malignancies
- Metastatic Cancer

## Interventions

- **DRUG:** INCAGN01876
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03126110
- **Lead sponsor:** Incyte Biosciences International Sàrl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-25
- **Primary completion:** 2021-11-09
- **Final completion:** 2021-11-09
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03126110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03126110, "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03126110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*